# Docosahexaenoic acid supplementation inhibits monocyte exhaustion memory formation during sepsis

**Authors:** Blake A. Caldwell, Yajun Wu, Susanti Ie, Amy Lucas, Benjamin Conacher, Yao Zhang, Babak Razani, Liwu Li

PMC · DOI: 10.1007/s00011-026-02194-w · Inflammation Research · 2026-02-18

## TL;DR

This study shows that DHA, an omega-3 fatty acid, can reduce monocyte exhaustion in sepsis, potentially preventing long-term immune issues.

## Contribution

The study reveals DHA's novel role in suppressing monocyte exhaustion memory through specific molecular mechanisms.

## Key findings

- DHA reduces expression of exhaustion markers CD38 and PD-L1 in monocytes.
- DHA treatment alters DNA methylation and inhibits STAT1/3 signaling pathways.
- DHA lowers CD157 and CCL2 levels, which are linked to tissue injury in sepsis.

## Abstract

Docosahexaenoic acid (DHA) is an omega-3 fatty acid with important roles in inflammation resolution. We tested the impact of DHA supplementation on monocyte exhaustion, an immune memory state contributing to chronic inflammation and immunosuppression following sepsis.

Ex vivo sepsis modeling was performed with C57BL/6 mouse bone marrow monocytes (BMMCs) and peripheral blood mononuclear cells (PBMCs) from septic patients.

BMMCs stimulated with lipopolysaccharide (100 ng/mL) for 5 days were supplemented with 60 µM DHA. Septic patient PBMCs were treated for 24 h with 0, 15, 30, 45, or 60 µM DHA.

Monocyte exhaustion was assayed by flow cytometry, qRT-PCR, and cytometric arrays. DNA methylation changes linked to exhaustion memory were measured by bisulfite pyrosequencing. Western blots were performed to link DHA treatment to altered cell signaling pathways in septic monocytes.

DHA supplementation suppresses the expression major exhaustion regulators CD38 and PD-L1 and dampens inflammatory cytokine transcription. These effects were mechanistically linked to STAT1/3 inhibition and accompanied by altered DNA methylation at immune regulators. DHA treatment also reduced CD157 cell surface levels and CCL2 secretion, both contributors to tissue invasion and injury during sepsis.

Our results support the therapeutic application of DHA for the prevention of chronic immune dysfunction in sepsis survivors.

The online version contains supplementary material available at 10.1007/s00011-026-02194-w.

## Linked entities

- **Genes:** CD38 (CD38 molecule) [NCBI Gene 952], CD274 (CD274 molecule) [NCBI Gene 29126], BST1 (bone marrow stromal cell antigen 1) [NCBI Gene 683], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774]
- **Chemicals:** DHA (PubChem CID 15608515)

## Full-text entities

- **Genes:** BST1 (bone marrow stromal cell antigen 1) [NCBI Gene 683] {aka CD157, cADPR2}, SOCS3 (suppressor of cytokine signaling 3) [NCBI Gene 9021] {aka ATOD4, CIS3, Cish3, SOCS-3, SSI-3, SSI3}, Ly6c1 (lymphocyte antigen 6 family member C1) [NCBI Gene 17067] {aka Ly-6C, Ly-6C1, Ly6c}, ACOD1 (aconitate decarboxylase 1) [NCBI Gene 730249] {aka CAD, IRG1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, FOXP1 (forkhead box P1) [NCBI Gene 27086] {aka 12CC4, HSPC215, MFH, QRF1, hFKH1B}, CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, Cd163 (CD163 antigen) [NCBI Gene 93671] {aka CD163v2, CD163v3}, Fut4 (fucosyltransferase 4) [NCBI Gene 14345] {aka CD15, FAL, FucT-IV, LeX, SSEA-1, Ssea1}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 733648], Anxa5 (annexin A5) [NCBI Gene 11747] {aka Anx5, CPB-I}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IL12A (interleukin 12A) [NCBI Gene 3592] {aka CLMF, IL-12A, NFSK, NKSF1, P35}, Fcgr3 (Fc receptor, IgG, low affinity III) [NCBI Gene 14131] {aka CD16}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Bst1 (bone marrow stromal cell antigen 1) [NCBI Gene 12182] {aka 114/A10, A530073F09, BP-3, Bp3, Bsta1, CD157}, CD14 (CD14 molecule) [NCBI Gene 929], ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, RUNX3 (RUNX family transcription factor 3) [NCBI Gene 864] {aka AML2, CBFA3, PEBP2aC}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, Marco (macrophage receptor with collagenous structure) [NCBI Gene 17167] {aka Ly112, Scara2}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 100127359] {aka FRAP1}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Il1r2 (interleukin 1 receptor, type II) [NCBI Gene 16178] {aka CD121b, Il1r-2}, ANXA6 (annexin A6) [NCBI Gene 309] {aka ANX6, CBP68, CPB-II, p68, p70}, Cd200r1 (CD200 receptor 1) [NCBI Gene 57781] {aka CD200R, Mox2r, OX2R}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 100126861] {aka Akt, PKB}, PIM1 (Pim-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5292] {aka PIM}, AK2 (adenylate kinase 2) [NCBI Gene 204] {aka ADK2}, TICAM2 (toll like receptor adaptor molecule 2) [NCBI Gene 100520421], CD200R1 (CD200 receptor 1) [NCBI Gene 131450] {aka CD200R, HCRTR2, MOX2R, OX2R}, Cx3cr1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 13051] {aka mCX3CR1}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}, CEBPB (CCAAT enhancer binding protein beta) [NCBI Gene 1051] {aka C/EBP-beta, IL6DBP, NF-IL6, TCF5}, Cxcr2 (C-X-C motif chemokine receptor 2) [NCBI Gene 12765] {aka CD128, CDw128, Cmkar2, Gpcr16, IL-8Rh, IL-8rb}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Cd80 (CD80 antigen) [NCBI Gene 12519] {aka B71, Cd28l, Ly-53, Ly53, MIC17, TSA1}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 100127158] {aka p70S6K}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, Cd14 (CD14 antigen) [NCBI Gene 12475], STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 396655], CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, PLAC8 (placenta associated 8) [NCBI Gene 51316] {aka C15, DGIC, PNAS-144, onzin}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 100736562] {aka CREB}, KLF7 (KLF transcription factor 7) [NCBI Gene 8609] {aka UKLF}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, H2 (histocompatibility-2, MHC) [NCBI Gene 111364] {aka H-2, MHC-II}
- **Diseases:** immune dysregulation (OMIM:614878), septic (MESH:D001170), Coma (MESH:D003128), Sepsis (MESH:D018805), chronic (MESH:D002908), M. tuberculosis infection (MESH:D014376), infection (MESH:D007239), Covid-19 (MESH:D000086382), immune (MESH:D007154), hemorrhagic shock (MESH:D012771), deaths (MESH:D003643), acute and chronic immune dysregulation (MESH:D001930), white blood cell disorders (MESH:D006402), non-small cell lung cancer (MESH:D002289), bleeding (MESH:D006470), Organ Failure (MESH:D009102), SIRS (MESH:D018746), cancer (MESH:D009369), mitochondrial disruption (MESH:D019958), PICS (MESH:D007249), injury (MESH:D014947), catabolism syndrome (MESH:D013577)
- **Chemicals:** PBS (MESH:D007854), NAD (MESH:D009243), PVDF (MESH:C024865), DMSO (MESH:D004121), reactive oxygen species (MESH:D017382), AZD2014 (MESH:C585537), L-glutamine (MESH:D005973), CO2 (MESH:D002245), lipid (MESH:D008055), DHA (MESH:D004281), LPS (MESH:D008070), HDHA (-), propidium iodide (MESH:D011419), dextran (MESH:D003911), penicillin (MESH:D010406), CFSE (MESH:C087165), SDS (MESH:D012967), acrylamide (MESH:D020106), arachidonic acid (MESH:D016718), Omega-3 (MESH:D015525), streptomycin (MESH:D013307), cADPR (MESH:D036563), PI (MESH:D010716), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** F1012I, serine/threonine, W21007F, S17015F, L 16 V
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913356/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913356/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913356/full.md

---
Source: https://tomesphere.com/paper/PMC12913356